Chronic pancreatitis (CP) is a severely disabling disorder with potential detrimental effects on quality of life, gut function, and glucose homeostasis. Disease progression often results in irreversible morphological and functional abnormalities with development of chronic pain, mechanical obstruction, and pancreatic insufficiency. Along with comprehensive medical management, the concept of total pancreatectomy and islet autotransplantation (TP-AIT) was introduced 40 years ago for patients with intractable pain and preserved beta-cell function. With anticipated technical difficulties, total excision of the inflamed-disfigured gland is expected to alleviate the incapacitating visceral pain and correct other associated abdominal pathology. With retrieval of sufficient islet-cell mass, the autologous transplant procedure has the potential to maintain an euglycemic state without exogenous insulin requirement.
The reported herein case of CP-induced recalcitrant pain and foregut obstruction is exceptional because of the technical challenges in performing native pancreaticoduodenectomy in close proximity to the composite visceral allograft with complex vascular and gut reconstructions. Equally novel is transplanting the auto-islets in the liver-contained visceral allograft. Despite intravenous nutrition shortly after birth, liver transplantation at age 13, retransplantation with liver-contained visceral allograft at age 17 and TP-AIT at age 31, the 38-year-old recipient is currently pain free with full nutritional autonomy and normal glucose homeostasis.
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The modern era of pancreatic surgery has also witnessed advances in the management of CP. 5 With failure of comprehensive medical and interventional therapy, multiple surgical procedures including total pancreatectomy (TP) are indicated for patients with debilitating visceral pain, gastric-outlet obstruction, and biliary strictures. With advances in islet-cell isolation, TP has been increasingly utilized with autologous islet transplantation (TP-AIT) for patients with residual functional islet-cell mass. 6 With successful engraftment, normal glycemic control is maintained avoiding the development of "brittle diabetes" and the life-threatening hypoglycemic unawareness. 7, 8 This report is a testimony of recent advances in visceral-organ and islet-cell transplantation. Surgery is fully described with special emphasis on the technical feasibility of pancreaticoduodenectomy among composite visceral allograft recipients. Equally novel, is infusion of native islets into the allograft portal vein. Management strategies and outcome measures are also discussed throughout the recipient's 38-year medical journey.
| MATERIAL S AND ME THODS

| Visceral transplantation
Shortly after birth, the 38-year-old male developed midgut volvulus 
| Chronic pancreatitis
Eleven years after transplantation, the patient experienced acute pancreatitis and azathioprine was discontinued. Over a 3-year period, the patient suffered recurrent episodes that required frequent 
| Preoperative evaluation
Candidacy for TP-AIT was declared after full assessment of the visceral allograft and beta-cell functions. 10 The 
| Total pancreaticoduodenectomy
After extensive adhesiolysis, the pancreatic phlegmon was dissected from the infrarenal aortic vascular graft, posterior gastric wall, and retroperitoneal structures. The splenic and short gastric vessels were preserved with interruption of the pancreatic arterial perforators and venous channels. 
| Autologous islet transplantation
The ice-packed pancreata were transferred to Pittsburgh for islet isolation with a 4-hour round trip via ground transportation. The isolation process was performed utilizing the modified collagenasebased digestion method. 10 With a total volume of 12 mL of pellet tissue, the islet-enriched preparation was not purified.
Upon the islet's arrival, the patient was transferred to the interventional radiology suite and the islets were infused into the liver allograft left portal vein utilizing the transhepatic percutaneous technique after failure of multiple transjugular attempts (Figure 3 ).
With total isolation of 481 000 islet equivalents (IEQ), the islet plug was suspended in 750 mL containing 8017 IEQ\kg and 4000 units of heparin (60 U/kg) that were infused over 4 hours. With an initial reading of 7 mm Hg, the portal venous pressure was continuously monitored and never exceeded 22 mm Hg. Cold ischemia was 10 hours and 56 minutes. were discontinued with full restoration of oral tolerance.
| Follow-up
Two months after discharge, patient was readmitted with gastrointestinal bleeding and an INR of 9 that required discontinuation of warfarin therapy. Within 2 weeks, he was readmitted with metabolic encephalopathy and serum ammonia level of 95 μmol/L. A month later, he suffered another episode of severe encephalopathy that mandated TIPS occlusion. At the 30-month follow-up point, a CT angiography demonstrated long-term patency of the visceral allograft axial blood supply and the native portacaval shunt ( Figure 5 ).
As of January 2018, the patient continued to be pain and insulin free with no neurological symptoms enjoying unrestricted oral diet with normal glucose levels.
| Glucose homeostasis and islet graft function
Fasting blood glucose and HbA 1c were used as metabolic markers of glucose homeostasis. Beta-cell function was periodically quantified by measuring the stimulated C-peptide and insulin levels at 4, 16, 30, 55, and 69 months after TP-AIT. The standard mixed-meal tolerance test (MMTT) was utilized and glucose, C-peptide, and insulin blood levels were measured at 0, 30, 60, 90, 120, 180, 240, and 300 minutes. 10, 12, 13 With discontinuation of TPN therapy, there was no further need for exogenous insulin. Throughout the 78-month study period, maximal fasting blood glucose was less than 120 mg/dL, HbA 1c never exceeded 5.9%, and C-peptide was always detectable with a minimal value of 0.4 ng/mL ( Figure 6 ). MMTT also showed adequate beta-cell function with sustained levels of stimulated endogenous insulin and C-peptide secretion ( Figure 7) . Interestingly, there was some periodic fluctuation in the stimulated peak and trough levels compared to normal controls. 13 This could be explained by the unpredictability of the intestinal allograft absorptive capacity and the coexistence of 2 distinct islet-cell masses operating in 2 different microenvironments.
With suppressed C-peptide values at the 55-month follow-up mark, the possibility of ongoing beta-cell injury was entertained.
This was evaluated by measuring the liberated demethylated insulin gene in the peripheral blood utilizing a novel genomic assay. The obtained results showed no evidence of circulating demethylated insulin gene indicating the lack of active beta-cell destruction.
| D ISCUSS I ON
This report is the first to address the technical feasibility, distinctiveness, and outcome of TP-AIT in a composite visceral allograft recipient. Despite complexity of the surgical field, the procedure was safely performed with protection of both the visceral allograft and native spleen vascular structures. Retaining the splenic circulation was essential to maintain shunt patency and venous drainage of the native stomach. The preserved spleen was also crucial for the recipient's further long-term survival with reduced risk of PTLD, GVHD, and overwhelming sepsis. 1, 9, 11 This article featured few novel observations concerning autoislet retrieval and transplantation. A high islet yield was achievable despite the deleterious effect of protracted total ischemia time compounded with 22-year exposure to diabetogenic immunosuppression therapy. 8, 10 The splenic preservation technique extended the warm ischemia with the inability to implement cold vascular flushing and the remote isolation prolonged the cold ischemia time. 15 Equally novel is engraftment of the auto-islets in the liver allograft. The unpurified islets were delivered to the allograft left portal vein utilizing the percutaneous transhepatic novel approach after failure of the transjugular technique. encephalopathy, the shunt was occluded after 6 months without compromising patency of the main portal vein.
In conclusion, TP-AIT is technically feasible after composite visceral transplantation with potential successful outcome. The primary therapeutic endpoints of narcotic-free pain relief and reestablishment of nutritional autonomy are achievable with preservation of normal glucose homeostasis. It is reasonable to believe that the maintenance of the euglycemic state documented herein is the result of the cumulative function of both the visceral allograft residual allo-islets and the successfully transplanted auto-islets.
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Such a notion could be partially supported by the reported herein and previously published collective observation of biphasic stimulatory endocrine response, sustained C-peptide values, absence of hypoglycemic unresponsiveness, and long-term engraftment of the visceral allograft.
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